These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 31107146

  • 1. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli.
    Al-Tamimi M, Abu-Raideh J, Albalawi H, Shalabi M, Saleh S.
    Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
    [Abstract] [Full Text] [Related]

  • 2. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J, Leverstein-Van Hall M, Kortmann W, Verlind J, Mulder F, Scharringa J, Fluit A, Ekkelenkamp M.
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [Abstract] [Full Text] [Related]

  • 3. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S, Gaind R, Ranjan R, Deb M.
    J Infect Dev Ctries; 2009 Nov 21; 4(1):24-9. PubMed ID: 20130375
    [Abstract] [Full Text] [Related]

  • 4. Is There an Association Between Use of Amoxicillin-Clavulanate and Resistance to Third-Generation Cephalosporins in Klebsiella pneumoniae and Escherichia coli at the Hospital Level?
    Marquet A, Vibet MA, Caillon J, Javaudin F, Chapelet G, Montassier E, Batard E.
    Microb Drug Resist; 2018 Sep 21; 24(7):987-994. PubMed ID: 29489447
    [Abstract] [Full Text] [Related]

  • 5. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B, Soubirou JF, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A.
    Antimicrob Agents Chemother; 2016 Jan 21; 60(1):424-30. PubMed ID: 26525800
    [Abstract] [Full Text] [Related]

  • 6. Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
    Thelen H, Dilworth TJ, Mercier RC.
    Chemotherapy; 2022 Jan 21; 67(4):261-268. PubMed ID: 36417841
    [Abstract] [Full Text] [Related]

  • 7. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
    Al-Tamimi M, Albalawi H, Shalabi M, Abu-Raideh J, Khasawneh AI, Alhaj F.
    Ann Clin Microbiol Antimicrob; 2022 May 22; 21(1):20. PubMed ID: 35599329
    [Abstract] [Full Text] [Related]

  • 8. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T, Jeinić L, Smitran A, Petković M.
    Srp Arh Celok Lek; 2013 May 22; 141(11-12):775-9. PubMed ID: 24502096
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K.
    Int Urol Nephrol; 2015 Jul 22; 47(7):1059-66. PubMed ID: 26026972
    [Abstract] [Full Text] [Related]

  • 10. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA, Xancal-Salvador LF, Esteban-Kenel V, Tello-Mercado AC, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Ponce-de-Leon A, Gonzalez-Lara MF.
    J Glob Antimicrob Resist; 2024 Sep 22; 38():212-215. PubMed ID: 38945364
    [Abstract] [Full Text] [Related]

  • 11. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
    Alsubaie MA, Alsuheili AZ, Aljehani MN, Alothman AA, Alzahrani AS, Mohammedfadel HA, Alnajjar AA.
    Pediatr Int; 2023 Sep 22; 65(1):e15620. PubMed ID: 37735838
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP.
    BMC Infect Dis; 2016 Nov 03; 16(1):620. PubMed ID: 27806687
    [Abstract] [Full Text] [Related]

  • 13. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    Arch Intern Med; 2008 Sep 22; 168(17):1897-902. PubMed ID: 18809817
    [Abstract] [Full Text] [Related]

  • 14. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP, Shams A, Montelin H, Lagerbäck P, Tängdén T.
    Int J Antimicrob Agents; 2019 Jan 22; 53(1):74-79. PubMed ID: 30236958
    [Abstract] [Full Text] [Related]

  • 15. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.
    Antimicrob Agents Chemother; 2013 May 22; 57(5):2109-13. PubMed ID: 23439636
    [Abstract] [Full Text] [Related]

  • 16. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
    Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF.
    World J Urol; 2013 Dec 22; 31(6):1427-32. PubMed ID: 23358791
    [Abstract] [Full Text] [Related]

  • 17. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb 22; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 18. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, Hernández JR, Pascual A.
    Clin Infect Dis; 2006 Dec 01; 43(11):1407-14. PubMed ID: 17083012
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL.
    Int J Antimicrob Agents; 2023 Aug 01; 62(2):106858. PubMed ID: 37211261
    [Abstract] [Full Text] [Related]

  • 20. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.
    J Antimicrob Chemother; 2006 Jun 01; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.